IL-18-secreting multiantigen targeting CAR T cells eliminate antigen-low myeloma in an immunocompetent mouse model

2.

Cancer Stat Facts: Myeloma. National Cancer Institute

. Accessed 14 February 2024. https://seer.cancer.gov/statfacts/html/mulmy.html.

3.

Moreau

P

,

Attal

M

,

Facon

T

.

Frontline therapy of multiple myeloma

.

Blood

.

2015

;

125

(

20

):

3076

-

3084

.

4.

Mikkilineni

L

,

Kochenderfer

JN

.

CAR T cell therapies for patients with multiple myeloma

.

Nat Rev Clin Oncol

.

2021

;

18

(

2

):

71

-

84

.

5.

Van De Donk

NWCJ

,

Richardson

PG

,

Malavasi

F

.

CD38 antibodies in multiple myeloma: back to the future

.

Blood

.

2018

;

131

(

1

):

13

-

29

.

6.

Mikkilineni

L

,

Kochenderfer

JN

.

Chimeric antigen receptor T-cell therapies for multiple myeloma

.

Blood

.

2017

;

130

(

24

):

2594

-

2602

.

7.

FDA approves idecabtagene vicleucel for multiple myeloma

. 2021. Accessed 14 February 2024. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-idecabtagene-vicleucel-multiple-myeloma.

8.

FDA approves ciltacabtagene autoleucel for relapsed or refractory multiple myeloma

. 2022. Accessed 14 February 2024. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-ciltacabtagene-autoleucel-relapsed-or-refractory-multiple-myeloma.

9.

Rodriguez-Otero

P

,

Ailawadhi

S

,

Arnulf

B

, et al.

Ide-cel or standard regimens in relapsed and refractory multiple myeloma

.

N Engl J Med

.

2023

;

388

(

11

):

1002

-

1014

.

10.

San-Miguel

J

,

Dhakal

B

,

Yong

K

, et al.

Cilta-cel or standard care in lenalidomide-refractory multiple myeloma

.

N Engl J Med

.

2023

;

389

(

4

):

335

-

347

.

11.

Brudno

JN

,

Maric

I

,

Hartman

SD

, et al.

T cells genetically modified to express an anti-B-cell maturation antigen chimeric antigen receptor with a CD28 costimulatory moiety cause remissions of poor-prognosis relapsed multiple myeloma

.

J Clin Oncol

.

2018

;

36

(

22

):

2267

-

2280

.

12.

Cohen

AD

,

Garfall

AL

,

Stadtmauer

EA

, et al.

B cell maturation antigen – specific CAR T cells are clinically active in multiple myeloma

.

J Clin Invest

.

2019

;

129

(

6

):

2210

-

2221

.

13.

Da Vià

MC

,

Dietrich

O

,

Truger

M

, et al.

Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma

.

Nat Med

.

2021

;

27

(

4

):

616

-

619

.

14.

Truger

MS

,

Duell

J

,

Zhou

X

, et al.

Single- and double-hit events in genes encoding immune targets before and after T cell–engaging antibody therapy in MM

.

Blood Adv

.

2021

;

5

(

19

):

3794

-

3798

.

15.

Lee

L

,

Lim

WC

,

Galas-Filipowicz

D

, et al.

Limited efficacy of APRIL CAR in patients with multiple myeloma indicate challenges in the use of natural ligands for CAR T-cell therapy

.

J Immunother Cancer

.

2023

;

11

(

6

):

e006699

.

16.

Pegram

HJ

,

Lee

JC

,

Hayman

EG

, et al.

Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning

.

Blood

.

2012

;

119

(

18

):

4133

-

4141

.

17.

Avanzi

MP

,

Yeku

O

,

Li

X

, et al.

Engineered tumor-targeted T cells mediate enhanced anti-tumor efficacy both directly and through activation of the endogenous immune system

.

Cell Rep

.

2018

;

23

(

7

):

2130

-

2141

.

18.

Hu

B

,

Ren

J

,

Luo

Y

, et al.

Augmentation of antitumor immunity by human and mouse CAR T cells secreting IL-18

.

Cell Rep

.

2017

;

20

(

13

):

3025

-

3033

.

19.

Ruella

M

,

Barrett

DM

,

Kenderian

SS

, et al.

Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies

.

J Clin Invest

.

2016

;

126

(

10

):

3814

-

3826

.

20.

Katsarou

A

,

Sjöstrand

M

,

Naik

J

, et al.

Combining a CAR and a chimeric costimulatory receptor enhances T cell sensitivity to low antigen density and promotes persistence

.

Sci Transl Med

.

2021

;

13

(

623

):

eabh1962

.

21.

Hirabayashi

K

,

Du

H

,

Xu

Y

, et al.

Dual-targeting CAR-T cells with optimal co-stimulation and metabolic fitness enhance antitumor activity and prevent escape in solid tumors

.

Nat Cancer

.

2021

;

2

(

9

):

904

-

918

.

22.

Majzner

RG

,

Rietberg

SP

,

Sotillo

E

, et al.

Tuning the antigen density requirement for CAR T-cell activity

.

Cancer Discov

.

2020

;

10

(

5

):

702

-

723

.

23.

Hamieh

M

,

Dobrin

A

,

Cabriolu

A

, et al.

CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape

.

Nature

.

2019

;

568

(

7750

):

112

-

116

.

24.

Mansilla-Soto

J

,

Eyquem

J

,

Haubner

S

, et al.

HLA-independent T cell receptors for targeting tumors with low antigen density

.

Nat Med

.

2022

;

28

(

2

):

345

-

352

.

25.

Gogishvili

T

,

Danhof

S

,

Prommersberger

S

, et al.

SLAMF7-CAR T cells eliminate myeloma and confer selective fratricide of SLAMF7+ normal lymphocytes

.

Blood

.

2017

;

130

(

26

):

2838

-

2847

.

26.

Smith

EL

,

Harrington

K

,

Staehr

M

, et al.

Supplementary materials for: GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells

.

Sci Transl Med

.

2019

;

11

(

485

):

eaau7746

.

27.

Mailankody

S

,

Devlin

SM

,

Landa

J

, et al.

GPRC5D-targeted CAR T cells for myeloma

.

N Engl J Med

.

2022

;

387

(

13

):

1196

-

1206

.

28.

Radhakrishnan

S V

,

Luetkens

T

,

Scherer

SD

, et al.

CD229 CAR T cells eliminate multiple myeloma and tumor propagating cells without fratricide

.

Nat Commun

.

2020

;

11

(

1

):

798

.

29.

Sun

C

,

Mahendravada

A

,

Ballard

B

, et al.

Safety and efficacy of targeting CD138 with a chimeric antigen receptor for the treatment of multiple myeloma

.

Oncotarget

.

2019

;

10

(

24

):

2369

-

2383

.

30.

Drent

E

,

Groen

RWJ

,

Noort

WA

, et al.

Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma

.

Haematologica

.

2016

;

101

(

5

):

616

-

625

.

31.

Novak

AJ

,

Darce

JR

,

Arendt

BK

, et al.

Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival

.

Blood

.

2004

;

103

(

2

):

689

-

694

.

32.

Moreaux

J

,

Legouffe

E

,

Jourdan

E

, et al.

BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone

.

Blood

.

2004

;

103

(

8

):

3148

-

3157

.

33.

Garfall

AL

,

Maus

MV

,

Hwang

W-T

, et al.

Chimeric antigen receptor T cells against CD19 for multiple myeloma

.

N Engl J Med

.

2015

;

373

(

11

):

1040

-

1047

.

34.

Shah

NN

,

Johnson

BD

,

Schneider

D

, et al.

Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial

.

Nat Med

.

2020

;

26

(

10

):

1569

-

1575

.

35.

Larson

SM

,

Walthers

CM

,

Ji

B

, et al.

CD19/CD20 bispecific chimeric antigen receptor (CAR) in naive/memory T cells for the treatment of relapsed or refractory non-Hodgkin lymphoma

.

Cancer Discov

.

2023

;

13

(

3

):

580

-

597

.

36.

Lee

L

,

Draper

B

,

Chaplin

N

, et al.

An APRIL-based chimeric antigen receptor for dual targeting of BCMA and TACI in multiple myeloma

.

Blood

.

2018

;

131

(

7

):

746

-

758

.

37.

Wong

DP

,

Roy

NK

,

Zhang

K

, et al.

A BAFF ligand-based CAR-T cell targeting three receptors and multiple B cell cancers

.

Nat Commun

.

2022

;

13

(

1

):

217

.

38.

Fernández de Larrea

C

,

Staehr

M

,

Lopez

AV

, et al.

Defining an optimal dual-targeted CAR T-cell therapy approach simultaneously targeting BCMA and GPRC5D to prevent BCMA escape–driven relapse in multiple myeloma

.

Blood Cancer Discov

.

2020

;

1

(

2

):

146

-

154

.

39.

Jaspers

JE

,

Khan

JF

,

Godfrey

WD

, et al.

IL-18-secreting CAR T cells targeting DLL3 are highly effective in small cell lung cancer models

.

J Clin Invest

.

2023

;

133

(

9

):

e166028

.

40.

Svoboda

J

,

Landsburg

DL

,

Chong

EA

, et al.

Fourth generation HUCART19-IL18 produces durable responses in lymphoma patients previously relapsed/refractory to anti-CD19 CAR T-cell theraphy

.

Hematol Oncol

.

2023

;

41

(

S2

):

35

-

37

.

41.

Hofgaard

PO

,

Jodal

HC

,

Bommert

K

, et al.

A novel mouse model for multiple myeloma (MOPC315.BM) that allows noninvasive spatiotemporal detection of osteolytic disease

.

PLoS One

.

2012

;

7

(

12

):

e51892

.

42.

Schmidts

A

,

Ormhøj

M

,

Choi

BD

, et al.

Rational design of a trimeric APRIL-based CAR-binding domain enables efficient targeting of multiple myeloma

.

Blood Adv

.

2019

;

3

(

21

):

3248

-

3260

.

43.

Carpenter

RO

,

Evbuomwan

MO

,

Pittaluga

S

, et al.

B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma

.

Clin Cancer Res

.

2013

;

19

(

8

):

2048

-

2060

.

44.

Lam

N

,

Trinklein

ND

,

Buelow

B

,

Patterson

GH

,

Ojha

N

,

Kochenderfer

JN

.

Anti-BCMA chimeric antigen receptors with fully human heavy-chain-only antigen recognition domains

.

Nat Commun

.

2020

;

11

(

1

):

283

. 14.

45.

Qin

H

,

Dong

Z

,

Wang

X

, et al.

CAR T cells targeting BAFF-R can overcome CD19 antigen loss in B cell malignancies

.

Sci Transl Med

.

2019

;

11

(

511

):

eaaw9414

.

46.

Tirier

SM

,

Mallm

JP

,

Steiger

S

, et al.

Subclone-specific microenvironmental impact and drug response in refractory multiple myeloma revealed by single-cell transcriptomics

.

Nat Commun

.

2021

;

12

(

1

):

6960

.

47.

Feucht

J

,

Sun

J

,

Eyquem

J

, et al.

Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency

.

Nat Med

.

2019

;

25

(

1

):

82

-

88

.

48.

Long

AH

,

Haso

WM

,

Shern

JF

, et al.

4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors

.

Nat Med

.

2015

;

21

(

6

):

581

-

590

.

49.

Weber

EW

,

Parker

KR

,

Sotillo

E

, et al.

Transient rest restores functionality in exhausted CAR-T cells through epigenetic remodeling

.

Science

.

2021

;

372

(

6537

):

eaba1786

.

50.

Guedan

S

,

Posey

AD

,

Shaw

C

, et al.

Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation

.

JCI Insight

.

2018

;

3

(

1

):

e96976

.

51.

Li

G

,

Boucher

JC

,

Kotani

H

, et al.

4-1BB enhancement of CAR T function requires NF-κB and TRAFs

.

JCI Insight

.

2018

;

3

(

18

):

e121322

-

18

.

52.

Maude

SL

,

Frey

N

,

Shaw

PA

, et al.

Chimeric antigen receptor T cells for sustained remissions in leukemia

.

N Engl J Med

.

2014

;

371

(

16

):

1507

-

1517

.

53.

Lee

DW

,

Kochenderfer

JN

,

Stetler-Stevenson

M

, et al.

T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial

.

Lancet

.

2015

;

385

(

9967

):

517

-

528

.

54.

James

SE

,

Chen

S

,

Ng

BD

, et al.

Leucine zipper-based sorting system enables generation of multi-functional CAR T cells

.

bioRxiv

.

2023

.

55.

Morris

EC

,

Neelapu

SS

,

Giavridis

T

,

Sadelain

M

.

Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy

.

Nat Rev Immunol

.

2022

;

22

(

2

):

85

-

96

.

56.

Brudno

JN

,

Kochenderfer

JN

.

J.N. K. Toxicities of chimeric antigen receptor T cells: recognition and management

.

Blood

.

2016

;

127

(

26

):

3321

-

3330

.

57.

Shimabukuro-Vornhagen

A

,

Gödel

P

,

Subklewe

M

, et al.

Cytokine release syndrome

.

J Immunother Cancer

.

2018

;

6

(

1

):

56

.

58.

Legut

M

,

Gajic

Z

,

Guarino

M

, et al.

A genome-scale screen for synthetic drivers of T cell proliferation

.

Nature

.

2022

;

603

(

7902

):

728

-

735

.

59.

Croft

M

.

The role of TNF superfamily members in T-cell function and diseases

.

Nat Rev Immunol

.

2009

;

9

(

4

):

271

-

285

.

60.

Dinarello

CA

.

IL-18: AtH1-inducing, proinflammatory cytokine and new member of the IL-1 family

.

J Allergy Clin Immunol

.

1999

;

103

(

1 Pt 1

):

11

-

24

.

61.

Torigoe

K

,

Ushio

S

,

Okura

T

, et al.

Purification and characterization of the human interleukin-18 receptor

.

J Biol Chem

.

1997

;

272

(

41

):

25737

-

25742

.

62.

Weinstock

JV

,

Blum

A

,

Metwali

A

,

Elliott

D

,

Arsenescu

R

.

IL-18 and IL-12 signal through the NF-kappa B pathway to induce NK-1R expression on T cells

.

J Immunol

.

2003

;

170

(

10

):

5003

-

5007

.

63.

Choi

BK

,

Lee

DY

,

Lee

DG

, et al.

4-1BB signaling activates glucose and fatty acid metabolism to enhance CD8 + T cell proliferation

.

Cell Mol Immunol

.

2017

;

14

(

9

):

748

-

757

.

64.

Boroughs

AC

,

Larson

RC

,

Marjanovic

ND

, et al.

A distinct transcriptional program in human CAR T cells bearing the 4-1BB signaling domain revealed by scRNA-seq

.

Mol Ther

.

2020

;

28

(

12

):

2577

-

2592

.

65.

Pahl

HL

.

Activators and target genes of Rel/NF-κB transcription factors

.

Oncogene

.

1999

;

18

(

49

):

6853

-

6866

.

66.

Boston University NF-kB Transcription Factors

.

NF-kB Target Genes

. Accessed 14 February 2024. https://www.bu.edu/nf-kb/gene-resources/target-genes/.

67.

Hinz

M

,

Lemke

P

,

Anagnostopoulos

I

, et al.

Nuclear factor κB–dependent gene expression profiling of hodgkin’s disease tumor cells, pathogenetic significance, and link to constitutive signal transducer and activator of transcription 5a activity

.

J Exp Med

.

2002

;

196

(

5

):

605

-

617

.

68.

Catz

SD

,

Johnson

JL

.

Transcriptional regulation of bcl-2 by nuclear factor κB and its significance in prostate cancer

.

Oncogene

.

2001

;

20

(

50

):

7342

-

7351

.

69.

Okamura

H

,

Tsutsui

H

,

Komatsu

T

, et al.

Cloning of a new cytokine that induces IFN-y production by T cells

.

Nature

.

1995

;

378

(

6552

):

88

-

91

.

70.

Göbel

TW

,

Schneider

K

,

Schaerer

B

, et al.

IL-18 stimulates the proliferation and IFN-γ release of CD4+ T cells in the chicken: conservation of a Th1-like system in a nonmammalian species

.

J Immunol

.

2003

;

171

(

4

):

1809

-

1815

.

71.

Castro

F

,

Cardoso

AP

,

Gonçalves

RM

,

Serre

K

,

Oliveira

MJ

.

Interferon-gamma at the crossroads of tumor immune surveillance or evasion

.

Front Immunol

.

2018

;

9

:

847

.

72.

Smeltz

RB

.

Profound enhancement of the IL-12/IL-18 pathway of IFN-gamma secretion in human CD8+ memory T cell subsets via IL-15

.

J Immunol

.

2007

;

178

(

8

):

4786

-

4792

.

73.

Okamoto

I

,

Kohno

K

,

Tanimoto

T

,

Ikegami

H

,

Kurimoto

M

.

Development of CD8+ effector T cells is differentially regulated by IL-18 and IL-12

.

J Immunol

.

1999

;

162

(

6

):

3202

-

3211

.

74.

Labanieh

L

,

Mackall

CL

.

CAR immune cells: design principles, resistance and the next generation

.

Nature

.

2023

;

614

(

7949

):

635

-

648

.

75.

Eyquem

J

,

Mansilla-Soto

J

,

Giavridis

T

, et al.

Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection

.

Nature

.

2017

;

543

(

7643

):

113

-

117

.

76.

Gomes-Silva

D

,

Mukherjee

M

,

Srinivasan

M

, et al.

Tonic 4-1BB costimulation in chimeric antigen receptors impedes T cell survival and is vector-dependent

.

Cell Rep

.

2017

;

21

(

1

):

17

-

26

.

77.

Haabeth

OAW

,

Hennig

K

,

Fauskanger

M

,

Løset

GÅ

,

Bogen

B

,

Tveita

A

.

CD4+T-cell killing of multiple myeloma cells is mediated by resident bone marrow macrophages

.

Blood Adv

.

2020

;

4

(

12

):

2595

-

2605

.

78.

Fauskanger

M

,

Haabeth

OAW

,

Skjeldal

FM

,

Bogen

B

,

Tveita

AA

.

Tumor killing by CD4+ T cells is mediated via induction of inducible nitric oxide synthase-dependent macrophage cytotoxicity

.

Front Immunol

.

2018

;

9

:

1684

.

79.

Balasubramani

A

,

Shibata

Y

,

Crawford

GE

,

Baldwin

AS

,

Hatton

RD

,

Weaver

CT

.

Modular utilization of distal cis-regulatory elements controls Ifng gene expression in T cells activated by distinct stimuli

.

Immunity

.

2010

;

33

(

1

):

35

-

47

.

80.

Sica

A

,

Dorman

L

,

Viggiano

V

, et al.

Interaction of NF-κB and NFAT with the interferon-γ promoter

.

J Biol Chem

.

1997

;

272

(

48

):

30412

-

30420

.

81.

Murray

PJ

.

Macrophage polarization

.

Annu Rev Physiol

.

2017

;

79

:

541

-

566

.

82.

Tugal

D

,

Liao

X

,

Jain

MK

.

Transcriptional control of macrophage polarization

.

Arterioscler Thromb Vasc Biol

.

2013

;

33

(

6

):

1135

-

1144

.

83.

Orecchioni

M

,

Ghosheh

Y

,

Pramod

AB

,

Ley

K

.

Macrophage polarization: different gene signatures in M1(Lps+) vs. classically and M2(LPS-) vs. alternatively activated macrophages

.

Front Immunol

.

2019

;

10

:

1084

.

84.

Kuznetsova

T

,

Prange

KHM

,

Glass

CK

,

de Winther

MPJ

.

Transcriptional and epigenetic regulation of macrophages in atherosclerosis

.

Nat Rev Cardiol

.

2020

;

17

(

4

):

216

-

228

.

85.

Ming-Chin Lee

K

,

Achuthan

AA

,

De Souza

DP

, et al.

Type I interferon antagonism of the JMJD3-IRF4 pathway modulates macrophage activation and polarization

.

Cell Rep

.

2022

;

39

(

3

):

110719

.

86.

Den Haan

JMM

,

Lehar

SM

,

Bevan

MJ

.

CD8+ but not CD8- dendritic cells cross-prime cytotoxic T cells in vivo

.

J Exp Med

.

2000

;

192

(

12

):

1685

-

1696

.

87.

Møller

SH

,

Wang

L

,

Ho

PC

.

Metabolic programming in dendritic cells tailors immune responses and homeostasis

.

Cell Mol Immunol

.

2022

;

19

(

3

):

370

-

383

.

88.

Helft

J

,

Böttcher

J

,

Chakravarty

P

, et al.

GM-CSF mouse bone marrow cultures comprise a heterogeneous population of CD11c+MHCII+ macrophages and dendritic cells

.

Immunity

.

2015

;

42

(

6

):

1197

-

1211

.

89.

Na

YR

,

Jung

D

,

Gu

GJ

,

Seok

SH

.

GM-CSF grown bone marrow derived cells are composed of phenotypically different dendritic cells and macrophages

.

Mol Cells

.

2016

;

39

(

10

):

734

-

741

.

90.

Leick

MB

,

Silva

H

,

Scarfò

I

, et al.

Non-cleavable hinge enhances avidity and expansion of CAR-T cells for acute myeloid leukemia

.

Cancer Cell

.

2022

;

40

(

5

):

494

-

508.e5

.

91.

Cohen

AD

,

Garfall

AL

,

Stadtmauer

EA

, et al.

B cell maturation antigen–specific CAR T cells are clinically active in multiple myeloma

.

J Clin Invest

.

2019

;

129

(

6

):

2210

-

2221

.

92.

Sun

Y

,

Yang

X-N

,

Yang

S-S

, et al.

Antigen-induced chimeric antigen receptor multimerization amplifies on-tumor cytotoxicity

.

Signal Transduct Target Ther

.

2023

;

8

(

1

):

445

.

93.

Alizadeh

D

,

Wong

RA

,

Gholamin

S

, et al.

IFNγ is critical for CAR T cell–mediated myeloid activation and induction of endogenous immunity

.

Cancer Discov

.

2021

;

11

(

9

):

2248

-

2265

.

94.

Hu

X

,

Ivashkiv

LB

.

Cross-regulation of signaling pathways by interferon-γ: implications for immune responses and autoimmune diseases

.

Immunity

.

2009

;

31

(

4

):

539

-

550

.

95.

Lee

H

,

Ahn

S

,

Maity

R

, et al.

Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma

.

Nat Med

.

2023

;

29

(

9

):

2295

-

2306

.

96.

Mantovani

A

,

Allavena

P

,

Marchesi

F

,

Garlanda

C

.

Macrophages as tools and targets in cancer therapy

.

Nat Rev Drug Discov

.

2022

;

21

(

11

):

799

-

820

.